NGeneBio Co., Ltd.
Financials
Valuation Metrics
NGeneBio Co., Ltd.'s Market Cap is ₩108B. At end of 2025 it was ₩576B. Ranked #2378 of 2,410 in KR market (top 99%), #1602 of 1,631 on KOSDAQ (top 98%), #228 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 99%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 10.84B KRW | KR#2,378/2,410 Sec#228/231 |
| Revenue | 41.76B KRW | KR#1,890/2,410 Sec#134/231 |
| Net Income | -5.31B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 70.62B KRW | KR#2,003/2,410 Sec#165/231 |
| Net Assets | 18.69B KRW | KR#2,302/2,410 Sec#216/231 |
| Employees | 96 | KR#1,666/2,410 Sec#130/231 |
| Value | ||
| P/B | 0.58x | KR#1,061/2,410 Sec#57/231 |
| P/S | 0.26x | KR#569/2,410 Sec#13/231 |
| FCF Yield | -78.76% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -28.39% | KR#2,162/2,410 Sec#171/231 |
| ROA | -7.51% | KR#2,035/2,410 Sec#150/231 |
| Op. Margin | -13.14% | KR#2,035/2,410 Sec#137/231 |
| Revenue Growth | 525.91% | KR#7/2,410 Sec#4/231 |
| Financial Health | ||
| Debt Ratio | 277.94% | KR#2,230/2,410 Sec#224/231 |
| Total Debt | 51.40B KRW | KR#999/2,410 Sec#69/231 |
| FCF | -8.54B KRW | KR#1,653/2,410 Sec#141/231 |
| Cash | 3.00B KRW | KR#2,158/2,410 Sec#204/231 |
| Current Ratio | 0.45x | KR#2,154/2,410 Sec#211/231 |
| Performance | ||
| 1Y Return | -81.44% | KR#2,349/2,410 Sec#228/231 |
| 1M Return | -11.78% | KR#1,821/2,410 Sec#180/231 |
| From 52W High | -90.07% | KR#2,392/2,410 Sec#229/231 |
| 1Y MDD | -90.07% | KR#2,394/2,410 Sec#229/231 |
| Trading | ||
| Volume | 967,673 shares | KR#4/2,410 Sec#1/231 |
| Trading Value | 688.7M KRW | KR#296/2,410 Sec#28/231 |
| Foreign Own. | 0.00% | KR—/2,410 Sec—/231 |
| Per Share | ||
| EPS | -330 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,162 KRW | KR#2,271/2,410 Sec#205/231 |
Company Info
Established in 2015, NGENBIO is a specialized NGS-based precision diagnostics company. It was listed on the KOSDAQ market in 2020 and expanded its pharmaceutical distribution business through an acquisition in 2025. The company provides gene extraction panels and data analysis software for conditions like breast cancer and blood cancer, and operates toxicology and molecular diagnostics services. NGENBIO supplies products to over 25 major medical institutions in Korea, expands overseas exports, and is leading the precision medicine market. NGENBIO is headquartered in Guro-gu, Seoul.